Clinical, pathologic, and imaging features and biological markers of uveal melanoma

Methods in Molecular Biology

Volumn 1102, Issue , 2014, Pages 397-425

  Rashid, Alia B ^a   Grossniklaus, Hans E ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Biological markers; Clinical features; Histopathology; Imaging; Prognosis; Uveal melanoma

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BIOLOGICAL MARKER; GAMMA GLUTAMYLTRANSFERASE; KI 67 ANTIGEN; LACTATE DEHYDROGENASE; MELAN A; MONOCLONAL ANTIBODY HMB 45; PROTEIN S 100; TUMOR MARKER;

ARTICLE; CANCER DIAGNOSIS; CANCER RISK; CANCER SCINTISCANNING; CANCER STAGING; CILIARY BODY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC IMAGING; ECHOGRAPHY; EYE INFLAMMATION; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER FUNCTION TEST; MICROCIRCULATION; MITOSIS RATE; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; OPTIC NERVE; PET-CT SCANNER; PIGMENTATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; THICKNESS; THORAX RADIOGRAPHY; TUMOR VOLUME; UVEA MELANOMA;

DIAGNOSTIC IMAGING; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER FUNCTION TESTS; MELANOMA; TUMOR MARKERS, BIOLOGICAL; UVEAL NEOPLASMS;

EID: 84891803741     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-62703-727-3_21     Document Type: Article

References (140)

1. Damato BE, Coupland SE (2012) Differences in uveal melanomas between men and women from the British Isles. Eye (Lond) 26(2): 292-299
2. Shields CL et al (2012) Clinical spectrum and prognosis of uveal melanoma based on Age at presentation in 8,033 cases. Retina 32(7): 1363-1372
3. Egan KM et al (1988) Epidemiologic aspects of uveal melanoma. Surv Ophthalmol 32(4):239-251
4. Singh AD, Bergman L, Seregard S (2005) Uveal melanoma: Epidemiologic aspects. Ophthalmol Clin North Am 18(1):75-84, viii
5. Hu DN et al (2005) Population-based incidence of uveal melanoma in various races and ethnic groups. Am J Ophthalmol 140(4): 612-617
6. Margo CE, Mulla Z, Billiris K (1998) Incidence of surgically treated uveal melanoma by race and ethnicity. Ophthalmology 105(6):1087-1090
7. Singh AD, Topham A (2003) Incidence of uveal melanoma in the United States: 1973-1997. Ophthalmology 110(5):956-961
8. Gallagher RP et al (1985) Risk factors for ocular melanoma: Western Canada Melanoma Study. J Natl Cancer Inst 74(4):775-778
9. Seddon JM et al (1990) Host factors, UV radiation, and risk of uveal melanoma. A casecontrol study. Arch Ophthalmol 108(9): 1274-1280
10. van Hees CL et al (1994) Are atypical nevi a risk factor for uveal melanoma? A case-control study. J Invest Dermatol 103(2):202-205
11. Tucker MA et al (1985) Sunlight exposure as risk factor for intraocular malignant melanoma. N Engl J Med 313(13):789-792
12. Singh AD, Turell ME, Topham AK (2011) Uveal melanoma: Trends in incidence, treatment, and survival. Ophthalmology 118(9):1881-1885
13. Bergman L et al (2002) Incidence of uveal melanoma in Sweden from 1960 to 1998. Invest Ophthalmol Vis Sci 43(8):2579-2583
14. Burr JM et al (2007) Survival from uveal melanoma in England and Wales 1986 to 2001. Ophthalmic Epidemiol 14(1):3-8
15. Kujala E, Makitie T, Kivela T (2003) Very long-term prognosis of patients with malignant uveal melanoma. Invest Ophthalmol Vis Sci 44(11):4651-4659
16. Seregard S, Kock E (1995) Prognostic indicators following enucleation for posterior uveal melanoma. A multivariate analysis of longterm survival with minimized loss to followup. Acta Ophthalmologica Scandinavica 73(4):340-344
17. Kaiserman I, Amer R, Péer J (2004) Liver function tests in metastatic uveal melanoma. Am J Ophthalmol 137(2):236-243
18. Bedikian AY (2006) Metastatic uveal melanoma therapy: Current options. Int Ophthalmol Clin 46(1):151-166
19. Kath R et al (1993) Prognosis and treatment of disseminated uveal melanoma. Cancer 72(7):2219-2223
20. Seddon JM et al (1983) A prognostic factor study of disease-free interval and survival following enucleation for uveal melanoma. Arch Ophthalmol 101(12):1894-1899
21. Chowers I, Amer R, Péer J (2002) The correlation among different immunostaining evaluation methods for the assessment of proliferative activity in uveal melanoma. Curr Eye Res 25(6):369-372
22. McLean IW et al (1983) Modifi cations of Callender's classification of uveal melanoma at the armed forces institute of pathology. Am J Ophthalmol 96(4):502-509
23. Edge SD, BD Carducci MA, Compton CC. (2009) Chapter 43: Malignant melanoma of the uvea. In: AJCC cancer staging manual. Springer: New York, NY
24. Grossniklaus HE, Kivela T, Harbour JW, Finger P (2011) Protocol for the examination of specimens from patients with uveal melanoma. College of American Pathologists Cancer Protocols 2011 [cited 2011 November 2011]; Uveal Melanoma 3.1.0.1:[Available from: Http://www.cap.org/apps/docs/committees/cancer/cancer- protocols/2012/ UvealMelanom-12protocol.pdf
25. Augsburger JJ, Gamel JW (1990) Clinical prognostic factors in patients with posterior uveal malignant melanoma. Cancer 66(7): 1596-1600
26. de la Cruz PO Jr, Specht CS, McLean IW (1990) Lymphocytic infi ltration in uveal malignant melanoma. Cancer 65(1):112-115
27. Folberg R et al (1992) The morphologic characteristics of tumor blood vessels as a marker of tumor progression in primary human uveal melanoma: A matched case-control study. Hum Pathol 23(11):1298-1305
28. Makitie T et al (1999) Microvascular loops and networks as prognostic indicators in choroidal and ciliary body melanomas. J Natl Cancer Inst 91(4):359-367
29. Diener-West M et al (2001) The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma, II: Characteristics of patients enrolled and not enrolled. COMS Report No. 17. Arch Ophthalmol 119(7): 951-965
30. Damato B, Coupland SE (2009) A reappraisal of the significance of largest basal diameter of posterior uveal melanoma. Eye (Lond) 23(12):2152-2160, quiz 2161-2
31. Diener-West M et al (2005) Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: Collaborative Ocular Melanoma Study Group Report No. 26. Arch Ophthalmol 123(12):1639-1643
32. Isager P, Ehlers N, Overgaard J (2004) Prognostic factors for survival after enucleation for choroidal and ciliary body melanomas. Acta Ophthalmol Scand 82(5):517-525
33. McLean IW, Keefe KS, Burnier MN (1997) Uveal melanoma. Comparison of the prognostic value of fi brovascular loops, mean of the ten largest nucleoli, cell type, and tumor size. Ophthalmology 104(5):777-780
34. Bellmann C et al (2010) Uveal melanoma: Management and outcome of patients with extraocular spread. Br J Ophthalmol 94(5):569-574
35. Coupland SE, Campbell I, Damato B (2008) Routes of extraocular extension of uveal melanoma: Risk factors and influence on survival probability. Ophthalmology 115(10):1778-1785
36. Diener-West M et al (1992) A review of mortality from choroidal melanoma. II. A metaanalysis of 5-year mortality rates following enucleation, through 1988. Arch Ophthalmol 110(2):245-250
37. Comparison of clinical, echographic, and histopathological measurements from eyes with medium-sized choroidal melanoma in the collaborative ocular melanoma study: COMS report no. 21. (2003) Arch Ophthalmol, 121(8): P. 1163-1171
38. Shields CL et al (2009) Metastasis of uveal melanoma millimeter-by- millimeter in 8033 consecutive eyes. Arch Ophthalmol 127(8):989-998
39. McLean IW et al (1995) Choroidal-ciliary body melanoma. A multivariate survival analysis of tumor location. Ophthalmology 102(7):1060-1064
40. Pach JM et al (1986) Prognostic factors in choroidal and ciliary body melanomas with extrascleral extension. Am J Ophthalmol 101(3):325-331
41. Affeldt JC et al (1980) Prognosis in uveal melanoma with extrascleral extension. Arch Ophthalmol 98(11):1975-1979
42. Font RL, Spaulding AG, Zimmerman LDM (1968) a clinicopathologic report of 54 cases. Transactions -American Academy of Ophthal ology and. Otolaryngology 72(6):877-895
43. Reese AB, Howard GM (1967) Flat uveal melanomas. Am J Ophthalmol 64(6): 1021-1028
44. Reichel E et al (1995) Occult choroidal melanoma presenting as a serous macular detachment. Retina 15(2):167-169
45. Yap EY, Robertson DM, Buettner H (1992) Scleritis as an initial manifestation of choroidal malignant melanoma. Ophthalmology 99(11):1693-1697
46. Shields CL et al (1995) Risk factors for growth and metastasis of small choroidal melanocytic lesions. Ophthalmology 102(9): 1351-1361
47. Shields CL et al (1996) Diffuse choroidal melanoma. Clinical features predictive of metastasis. Arch Ophthalmol 114(8):956-963
48. Shields JA, Shields CL (1999) Atlas of Intraocular Tumors. Lippincott Williams & Wilkins, Philadelphia, PA
49. Chaudhry IM, Moster MR, Augsburger JJ (1997) Iris ring melanoma masquerading as pigmentary glaucoma. Arch Ophthalmol 115(11):1480-1481
50. Diekstall F, Demeler U (1988) Therapyresistant increase in ocular pressure-A rare differential diagnosis: Ring melanoma. Fortschr Ophthalmol 85(1):98-100
51. Vasquez LM et al (2008) Ring melanoma of the ciliary body: Clinical and ultrasound biomicroscopic characteristics. Can J Ophthalmol 43(2):229-233
52. Demirci H et al (2002) Ring melanoma of the ciliary body: Report on twenty-three patients. Retina 22(6):698-706, quiz 852-3
53. Christmas NJ et al (1991) Secondary optic nerve tumors. Surv Ophthalmol 36(3): 196-206
54. Lindegaard J, Heegaard S, Prause JU (2002) Histopathologically verifi ed non-vascular optic nerve lesions in Denmark 1940-99. Acta Ophthalmol Scand 80(1):32-37
55. Shammas HF, Blodi FC (1978) Peripapillary choroidal melanomas. Extension along the optic nerve and its sheaths. Arch Ophthalmol 96(3):440-445
56. McLean MJ, Foster WD, Zimmerman LE (1977) Prognostic factors in small malignant melanomas of choroid and ciliary body. Arch Ophthalmol 95(1):48-58
57. Damato BE, Paul J, Foulds WS (1996) Risk factors for residual and recurrent uveal melanoma after trans-scleral local resection. Br J Ophthalmol 80(2):102-108
58. McCurdy J, Gamel J, McLean I (1991) A simple, effi cient, and reproducible method for estimating the malignant potential of uveal melanoma from routine H & E slides. Pathol Res Pract 187(8):1025-1027
59. Coleman K et al (1996) Prognostic value of morphometric features and the callender classification in uveal melanomas. Ophthalmology 103(10):1634-1641
60. Péer J et al (1994) Mean of the ten largest nucleoli, microcirculation architecture, and prognosis of ciliochoroidal melanomas. Ophthalmology 101(7):1227-1235
61. Seregard S et al (1998) Prognostic accuracy of the mean of the largest nucleoli, vascular patterns, and PC-10 in posterior uveal melanoma. Ophthalmology 105(3):485-491
62. Gamel JW, McCurdy JB, McLean IW (1992) A comparison of prognostic covariates for uveal melanoma. Invest Ophthalmol Vis Sci 33(6):1919-1922
63. van Diest PJ et al (1992) Reproducibility of mitosis counting in 2,469 breast cancer specimens: Results from the Multicenter Morphometric Mammary Carcinoma Project. Hum Pathol 23(6):603-607
64. Angi M et al (2011) Immunohistochemical assessment of mitotic count in uveal melanoma. Acta Ophthalmol 89(2):e155-e160
65. Tapia C et al (2006) Two mitosis-specific antibodies, MPM-2 and phospho-histone H3 (Ser28), allow rapid and precise determination of mitotic activity. Am J Surg Pathol 30(1):83-89
66. Folberg R et al (1997) The microcirculation of choroidal and ciliary body melanomas. Eye (Lond) 11(Pt 2):227-238
67. Vernon RB, Sage EH (1995) Between molecules and morphology. Extracellular matrix and creation of vascular form. Am J Pathol 147(4):873-883
68. Ajili F et al (2012) Prognostic impact of angiogenesis in nonmuscle invasive bladder cancer as defi ned by microvessel density after immunohistochemical staining for CD34. Ultrastruct Pathol 36(5):336-342
69. Benckert C et al (2012) Impact of microvessel density on lymph node metastasis and survival after curative resection of pancreatic cancer. Surg Today 42(2):169-176
70. Dutta S et al (2012) The relationship between tumour necrosis, tumour proliferation, local and systemic infl ammation, microvessel density and survival in patients undergoing potentially curative resection of oesophageal adenocarcinoma. Br J Cancer 106(4):702-710
71. Iakovlev VV et al (2012) Microvascular density as an independent predictor of clinical outcome in renal cell carcinoma: An automated image analysis study. Lab Invest 92(1):46-56
72. Wang J et al (2012) Lymphatic microvessel density as a prognostic factor in non-small cell lung carcinoma: A meta-analysis of the literature. Mol Biol Rep 39(5):5331-5338
73. Folkman J (1985) Tumor angiogenesis. Adv Cancer Res 43:175-203
74. Weidner N et al (1991) Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 324(1):1-8
75. Folberg R et al (1993) The prognostic value of tumor blood vessel morphology in primary uveal melanoma. Ophthalmology 100(9):1389-1398
76. Rummelt V et al (1994) Microcirculation architecture of melanocytic nevi and malignant melanomas of the ciliary body and choroid. A comparative histopathologic and ultrastructural study. Ophthalmology 101(4):718-727
77. Histopathologic characteristics of uveal melanomas in eyes enucleated from the Collaborative Ocular Melanoma Study. (1998) COMS report no. 6. Am J Ophthalmol 125(6):745-766
78. McLean IW, Saraiva VS, Burnier MN (2004) Pathological and prognostic features of uveal melanomas. Can J Ophthalmol 39(4):343-350
79. Shammas HF, Blodi FC (1977) Prognostic factors in choroidal and ciliary body melanomas. Arch Ophthalmol 95(1):63-69
80. Ly LV et al (2010) Infl ammatory cytokines in eyes with uveal melanoma and relation with macrophage infi ltration. Invest Ophthalmol Vis Sci 51(11):5445-5451
81. Durie FH et al (1990) Analysis of lymphocytic infi ltration in uveal melanoma. Invest Ophthalmol Vis Sci 31(10):2106-2110
82. Gown AM et al (1986) Monoclonal antibodies specific for melanocytic tumors distinguish subpopulations of melanocytes. Am J Pathol 123(2):195-203
83. Steuhl KP et al (1993) Significance, specificity, and ultrastructural localization of HMB-45 antigen in pigmented ocular tumors. Ophthalmology 100(2):208-215
84. Ordonez NG, Ji XL, Hickey RC (1988) Comparison of HMB-45 monoclonal antibody and S-100 protein in the immunohisto-chemical diagnosis of melanoma. Am J Clin Pathol 90(4):385-390
85. Wick MR, Swanson PE, Rocamora A (1988) Recognition of malignant melanoma by monoclonal antibody HMB-45. An immunohistochemical study of 200 paraffi n-embedded cutaneous tumors. J Cutan Pathol 15(4): 201-207
86. Burnier MN Jr, McLean IW, Gamel JW (1991) Immunohistochemical evaluation of uveal melanocytic tumors. Expression of HMB-45, S-100 protein, and neuron-specific enolase. Cancer 68(4):809-814
87. Luyten GP et al (1996) Metastatic uveal melanoma. A morphologic and immunohistochemical analysis. Cancer 78(9):1967-1971
88. Schafer BW, Heizmann CW (1996) The S100 family of EF-hand calcium-binding proteins: Functions and pathology. Trends Biochem Sci 21(4):134-140
89. Baudier J, Glasser N, Gerard D (1986) Ions binding to S100 proteins. I. Calcium-and zinc-binding properties of bovine brain S100 alpha alpha, S100a (alpha beta), and S100b (beta beta) protein: Zn2+ regulates Ca2+ binding on S100b protein. J Biol Chem 261(18):8192-8203
90. Cochran AJ et al (1983) Detection of cytoplasmic S-100 protein in primary and metastatic intraocular melanomas. Invest Ophthalmol Vis Sci 24(8):1153-1155
91. Cochran AJ et al (1993) S-100 protein remains a practical marker for melanocytic and other tumours. Melanoma Res 3(5):325-330
92. Gerdes J et al (1984) Cell cycle analysis of a cell proliferation- associated human nuclear antigen defi ned by the monoclonal antibody Ki-67. J Immunol 133(4):1710-1715
93. Mooy CM et al (1990) Ki-67 immunostaining in uveal melanoma. The effect of preenucleation radiotherapy. Ophthalmology 97(10):1275-1280
94. Schilling H, Sehu KW, Lee WR (1997) A histologic study (including DNA quantifi cation and Ki-67 labeling index) in uveal melanomas after brachytherapy with ruthenium plaques. Invest Ophthalmol Vis Sci 38(10): 2081-2092
95. Chowers I et al (2001) Comparison of microcirculation patterns and MIB-1 immunoreactivity in iris and posterior uveal melanoma. Ophthalmology 108(2):367-371
96. Al-Jamal RT, Kivela T (2006) KI-67 immunopositivity in choroidal and ciliary body melanoma with respect to nucleolar diameter and other prognostic factors. Curr Eye Res 31(1):57-67
97. Chen YT et al (1996) Serological analysis of Melan-A(MART-1), a melanocyte-specific protein homogeneously expressed in human melanomas. Proc Natl Acad Sci U S A 93(12):5915-5919
98. Blessing K, Sanders DS, Grant JJ (1998) Comparison of immunohistochemical staining of the novel antibody melan-A with S100 protein and HMB-45 in malignant melanoma and melanoma variants. Histopathology 32(2):139-146
99. Heegaard S, Jensen OA, Prause JU (2000) Immunohistochemical diagnosis of malignant melanoma of the conjunctiva and uvea: Comparison of the novel antibody against melan-A with S100 protein and HMB-45. Melanoma Res 10(4):350-354
100. Fernandes BF et al (2007) Immunohistochemical expression of melan-A and tyrosinase in uveal melanoma. J Carcinog 6:6
101. Kivela T, Eskelin S, Kujala E (2006) Metastatic uveal melanoma. Int Ophthalmol Clin 46(1):133-149
102. Zakka KA et al (1980) Malignant melanoma. Analysis of an autopsy population. Ophthalmology 87(6):549-556
103. Gragoudas ES et al (1991) Survival of patients with metastases from uveal melanoma. Ophthalmology 98(3):383-389, discussion 390
104. Diener-West M et al (2004) Screening for metastasis from choroidal melanoma: The Collaborative Ocular Melanoma Study Group Report 23. J Clin Oncol 22(12):2438-2444
105. Donoso LA et al (1985) Metastatic uveal melanoma. Pretherapy serum liver enzyme and liver scan abnormalities. Arch Ophthalmol 103(6):796-798
106. Gombos DS et al (2004) Geographic disparities in diagnostic screening for metastatic uveal melanoma. Ophthalmology 111(12):2254-2258
107. Hicks C, Foss AJ, Hungerford JL (1998) Predictive power of screening tests for metastasis in uveal melanoma. Eye (Lond) 12(Pt 6):945-948
108. Mouriaux F et al (2012) Liver function testing is not helpful for early diagnosis of metastatic uveal melanoma. Ophthalmology 119(8):1590-1595
109. Eskelin S et al (1999) Screening for metastatic malignant melanoma of the uvea revisited. Cancer 85(5):1151-1159
110. Bedikian AY et al (1995) Treatment of uveal melanoma metastatic to the liver: A review of the M. D. Anderson Cancer Center experience and prognostic factors. Cancer 76(9):1665-1670
111. Leyvraz S et al (1997) Treatment of ocular melanoma metastatic to the liver by hepatic arterial chemotherapy. J Clin Oncol 15(7): 2589-2595
112. Mudhar HS et al (2004) A critical appraisal of the prognostic and predictive factors for uveal malignant melanoma. Histopathology 45(1):1-12
113. Bonfrer JM et al (1998) The luminescence immunoassay S-100: A sensitive test to measure circulating S-100B: Its prognostic value in malignant melanoma. Br J Cancer 77(12):2210-2214
114. Bosserhoff AK et al (1999) MIA, a novel serum marker for progression of malignant melanoma. Anticancer Res 19(4A):2691-2693
115. Rittling SR, Chambers AF (2004) Role of osteopontin in tumour progression. Br J Cancer 90(10):1877-1881
116. Bonfrer JM, Korse CM, Israels SP (1997) Serum S-100 has prognostic significance in malignant melanoma. Anticancer Res 17(4B):2975-2977
117. Hauschild A et al (1999) S100B protein detection in serum is a signifi cant prognostic factor in metastatic melanoma. Oncology 56(4):338-344
118. Kadkol SS et al (2006) Osteopontin expression and serum levels in metastatic uveal melanoma: A pilot study. Invest Ophthalmol Vis Sci 47(3):802-806
119. Reiniger IW et al (2005) "Melanoma inhibitory activity" (MIA): A promising serological tumour marker in metastatic uveal melanoma. Graefes Arch Clin Exp Ophthalmol 243(11):1161-1166
120. Hawkins BS (2004) The Collaborative Ocular Melanoma Study (COMS) randomized trial of pre-enucleation radiation of large choroidal melanoma: IV. Ten-year mortality findings and prognostic factors. COMS report number 24. Am J Ophthalmol 138(6):936-951
121. Meziani L et al (2012) Uveal metastasis revealing lung cancer. J Fr Ophtalmol 35(6):420-425
122. Shields CL et al (1997) Survey of 520 eyes with uveal metastases. Ophthalmology 104(8):1265-1276
123. Harada S et al (1983) Solitary pulmonary metastasis of choroidal malignant melanoma: Report of an unusual case. Endoscopy 15(6):363-364
124. Tishler M, Greif J, Topilsky M (1986) Solitary pulmonary metastasis of choroidal malignant melanoma simulating primary lung cancer. Eur J Respir Dis 68(3):215-217
125. Frenkel S et al (2009) Long-term survival of uveal melanoma patients after surgery for liver metastases. Br J Ophthalmol 93(8):1042-1046
126. Sato T et al (1997) Time to systemic metastases in patients with posterior uveal melanoma. Cancer Invest 15(2):98-105
127. Summanen P et al (1993) Survival of patients and metastatic and local recurrent tumor growth in malignant melanoma of the uvea after ruthenium plaque radiotherapy. Ophthalmic Surg 24(2):82-90
128. Feinstein EG et al (2010) Hepatic abnormalities identified on abdominal computed tomography at diagnosis of uveal melanoma. Arch Ophthalmol 128(3):319-323
129. Schoder H, Larson SM, Yeung HW (2004) PET/CT in oncology: Integration into clinical management of lymphoma, melanoma, and gastrointestinal malignancies. J Nucl Med 45(Suppl 1):72S-81S
130. Cohade C et al (2003) Direct comparison of (18)F-FDG PET and PET/CT in patients with colorectal carcinoma. J Nucl Med 44(11):1797-1803
131. Antoch G et al (2003) Whole-body dualmodality PET/CT and whole-body MRI for tumor staging in oncology. JAMA 290(24):3199-3206
132. Freudenberg LS et al (2004) Whole-body fl uorine-18 fl uordeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) in staging of advanced uveal melanoma. Surv Ophthalmol 49(5):537-540
133. Finger PT et al (2005) Whole body PET/CT for initial staging of choroidal melanoma. Br J Ophthalmol 89(10):1270-1274
134. Orcurto V et al (2012) (18) F-fluorodeoxyglucose positron emission tomography/computed tomography and magnetic resonance imaging in patients with liver metastases from uveal melanoma: Results from a pilot study. Melanoma Res 22(1): 63-69
135. Servois V et al (2010) Preoperative staging of liver metastases from uveal melanoma by magnetic resonance imaging (MRI) and fluorodeoxyglucose- positron emission tomography (FDG-PET). Eur J Surg Oncol 36(2):189-194
136. Wykoff CC et al (2011) Preoperative evaluation for patients with choroidal/ciliary body melanomas: What is necessary? Am J Ophthalmol 151(6):921-924
137. Hendler K et al (2011) Trends in liver function tests: A comparison with serum tumor markers in metastatic uveal melanoma (part 2). Anticancer Res 31(1):351-357
138. Missotten GS et al (2007) S-100B protein and melanoma inhibitory activity protein in uveal melanoma screening. A comparison with liver function tests. Tumour Biol 28(2):63-69
139. Harbour JW (2012) The genetics of uveal melanoma: An emerging framework for targeted therapy. Pigment Cell Melanoma Res 25(2):171-181
140. Francken AB et al (2006) Detection of metastatic disease in patients with uveal melanoma using positron emission tomography. Eur J Surg Oncol 32(7):780-784